Abemaciclib metabolite M18 hydrochloride

Mechanism of Action: Abemaciclib metabolite M18 hydrochloride supports customers evaluating CDK4/6 pathway effects on protein abundance and stability. By modulating cell-cycle phosphorylation networks, it can help assess downstream changes in protein complexes, transcriptional output, and degradation sensitivity of cell-cycle-regulated targets.

• PROTAC Ligand for CDK6: Abemaciclib metabolite M18 hydrochloride can be used as a targeting ligand in PROTAC designs to engage CDK6/related cell-cycle kinases. By recruiting an E3 ligase through a suitable linker, researchers can test whether M18-based binding promotes ubiquitination and degradation, enabling mechanistic studies of kinase turnover rather than simple inhibition.

• Investigate Degradation vs Inhibition: In PROTAC workflows, M18 hydrochloride can help distinguish degradation-driven phenotypes from occupancy-driven effects. Comparing PROTAC-mediated CDK6 degradation to abemaciclib-like inhibition clarifies whether downstream cell-cycle arrest results from reduced protein abundance, altered signaling dynamics, or compensatory pathway rewiring.

• Optimize Linker and E3 Recruitment: The metabolite scaffold of M18 hydrochloride is suitable for systematic PROTAC optimization, including linker length, attachment position, and E3 ligase choice. These variables can be tuned to maximize ternary complex formation, ubiquitin transfer efficiency, and degradation potency, while minimizing off-target degradation of other kinases.

• Map Resistance and Pathway Effects: Using M18-based PROTACs supports studies of resistance mechanisms that involve altered kinase stability, ubiquitin-proteasome processing, or compensatory CDK network remodeling. Degradation-focused experiments can reveal how changes in CDK6 abundance affect transcriptional programs and sensitivity to perturbations in cell-cycle regulation.

• Study Kinase Degradation Kinetics: M18 hydrochloride-derived PROTACs enable quantitative assessment of degradation kinetics, including onset time, extent of protein loss, and recovery after washout. Such time-resolved experiments help define degradation mechanisms, such as dependence on proteasome activity and E3 ligase engagement, and guide rational selection of PROTAC architectures.

Abemaciclib metabolite M18 hydrochloride is an abemaciclib-derived CDK4/6 ligand candidate for CDK-directed degrader exploration. The hydrochloride salt form may support handling and formulation of polar ligand analogs.

Structure: Abemaciclib metabolite M18 hydrochloride is an abemaciclib-derived CDK4/6 ligand form supplied as a hydrochloride salt. Its structure is expected to retain nitrogen-rich heteroaromatic and piperazine-containing features associated with CDK ligand recognition, while the salt form increases polarity relative to the neutral base.

Reactivity: For CDK-directed PROTAC exploration, linker attachment should be guided by a functional group that tolerates derivatization without disrupting CDK4/6 binding. Stable amide, carbamate, ether, or alkyl linker chemistries may be considered for pairing with CRBN, VHL, or IAP ligands once a suitable reactive vector is confirmed.